Breast cancer has grown to be the second leading cause of cancer-related deaths in women. Only a few treatment options are available for breast cancer due to the widespread occurrence of chemoresistance, which emphasizes the need to discover and develop new methods to treat this disease. Signal transducer and activator of transcription 3 (STAT3) is an early tumor diagnostic marker and is known to promote breast cancer malignancy. Recent clinical and preclinical data indicate the involvement of overexpressed and constitutively activated STAT3 in the progression, proliferation, metastasis and chemoresistance of breast cancer. Moreover, new pathways comprised of upstream regulators and downstream targets of STAT3 have been discovered. In addition, small molecule inhibitors targeting STAT3 activation have been found to be efficient for therapeutic treatment of breast cancer. This systematic review discusses the advances in the discovery of the STAT3 pathways and drugs targeting STAT3 in breast cancer. Video abstract.

中文翻译：

---

STAT3信号通路在乳腺癌中的作用。


乳腺癌已成为女性癌症相关死亡的第二大原因。由于化疗耐药性的广泛发生，乳腺癌只有少数治疗选择，这强调了发现和开发治疗这种疾病的新方法的必要性。信号转导器和转录激活剂 3 (STAT3) 是一种早期肿瘤诊断标志物，已知会促进乳腺癌恶变。最近的临床和临床前数据表明过表达和组成型激活的STAT3参与乳腺癌的进展、增殖、转移和化疗耐药。此外，还发现了由 STAT3 上游调节因子和下游靶标组成的新途径。此外，针对 STAT3 激活的小分子抑制剂已被发现可有效治疗乳腺癌。这篇系统综述讨论了乳腺癌中 STAT3 通路和靶向 STAT3 的药物的发现进展。视频摘要。